🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

33 results for “Viatris” Clear

  1. ACICLOVIR VIATRIS 500 mg, poudre pour solution injectable (I.V.), CHLORURE DE SODIUM 0,9 % B. BRAUN, solution injectable en ampoule

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  2. AMIKACINE VIATRIS 1 g, poudre pour solution injectable en flacon, CHLORURE DE SODIUM 0,9 % COOPER, solution pour perfusion

    Tour Hekla

    Patients with ventilator-associated tracheobronchitis

    phase 3 small molecule active

    1 trial

  3. Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  4. CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  5. Cenerimod

    Viatris Pharmaceuticals Co.,

    Lupus Erythematosus, Systemic

    phase 3 small molecule active

    2 trials

  6. Cenerimod 4 mg

    Viatris Pharmaceuticals Co.,

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  7. Cenerimod 4 mg, Cenerimod matching placebo

    Viatris Pharmaceuticals Co.,

    Moderate to severe systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  8. Cenerimod matching placebo, Cenerimod 4 mg

    Viatris Pharmaceuticals Co.,

    Moderate to severe systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  9. PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  10. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  11. REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion, NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  12. SODIUM CHLORIDE, LEVETIRACETAM VIATRIS 100 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  13. Selatogrel

    Viatris Pharmaceuticals Co.,

    Acute Myocardial Infarction

    phase 3 other active

    1 trial

  14. Selatogrel solution matching placebo, Selatogrel solution

    Viatris Pharmaceuticals Co.,

    Acute myocardial infarction (AMI)

    phase 3 small molecule active

    1 trial

  15. Tamoxifen Viatris 20 mg tabletter.

    The George Institute

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Tarlatamab, OXALIPLATINE VIATRIS 5 mg/ml, poudre pour solution pour perfusion, Dacarbazine "Lipomed", Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Temozolomide 100 mg hard capsules, OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Topotecan Accord Healthcare 4mg Powder for Concentrate for Solution for Infusion, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour per

    CERO THERAPEUTICS HOLDINGS, INC.

    Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)

    phase 3 small molecule active

    1 trial

  17. placebo of metformine, METFORMINE VIATRIS 500 mg, comprimé dispersible

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  18. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial

  19. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

  20. CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion, Alunbrig 30 mg film-coated tablets, Alunbrig 180 mg film-coated tablets, Pemetrexed Viatris 25 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    advanced ALK-positive non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  21. CISPLATINE VIATRIS 25 mg/25 ml, solution à diluer pour perfusion, Tecentriq 1 200 mg concentrate for solution for infusion, CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Paclitaxel Accord Healthcare 6 mg/ml solution à diluer pour perfusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    The George Institute

    Patients with locally advanced or metastasic Non-Small Cell Lung Carcinoma.

    phase 2 small molecule active

    1 trial

  22. DASATINIB VIATRIS 50 mg, comprimé pelliculé, DASATINIB VIATRIS 70 mg, comprimé pelliculé

    The George Institute

    acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  23. Inlyta 1 mg film-coated tablets, Inlyta 3 mg film-coated tablets, CELLTOP 50 mg, capsule molle, ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion

    ISTA Pharma Limited

    Ependymoma, Medulloblastoma

    phase 2 small molecule active

    1 trial

  24. Rapamune 1 mg/mL oral solution, Rapamune 0.5 mg coated tablets, Co-Trimoxazole Forte 160/800mg Tablets, Rapamune 2 mg coated tablets, adeno-associated virus, serotype 9 (AAV9), PREDNISONE VIATRIS 5 mg, comprimé sécable, PREDNISONE VIATRIS 1 mg, comprimé, PREDNISONE VIATRIS 20 mg, comprimé sécable, Prednisone Olikla 2.5 mg tablety, Prednisone Olikla 10 mg tablety, Prednisone Olikla 50 mg tablety, Rapamune 1 mg coated tablets

    Alexion Europe SAS

    BAG3 Mutation Associated Dilated Cardiomyopathy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources